Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 5/2019

01-09-2019 | Original Article

Serum level vitamin D and parathyroid hormone, and mortality, with or without chronic kidney disease

Authors: Chang Kyun Choi, Sun-Seog Kweon, Young-Hoon Lee, Hae-Sung Nam, Kyeong-Soo Park, So-Yeon Ryu, Seong-Woo Choi, Sun A. Kim, Min-Ho Shin

Published in: Journal of Bone and Mineral Metabolism | Issue 5/2019

Login to get access

Abstract

Levels of vitamin D and parathyroid hormone (PTH) are closely associated with renal function. We evaluated the associations among 25-hydroxyvitamin D (25OHD) levels, PTH levels, and mortality, and whether these associations varied by renal function. We used data from the Dong-gu Study, a population-based cohort in Korean adults. We analyzed the associations among intact PTH, 25OHD levels and mortality in 8580 participants. Hazard ratios (HRs) for mortality were calculated using Cox proportional hazards regression after adjusting for age, sex, month of sampling, lifestyle, and comorbidities. We also evaluated the effects of chronic kidney disease (CKD). A total of 860 deaths occurred during the follow-up period of 7.6 years. Compared to the first 25OHD quartile, the HRs of the second, third, and fourth quartiles were 0.96 [95% confidence interval (CI) 0.79–1.16], 0.84 (95% CI 0.68–1.02), and 0.71 (95% CI 0.57–0.89), respectively. The association between intact PTH levels and mortality varied by renal function, and was both nonlinear and significant only in subjects with CKD. Compared to the second intact PTH quartile in such subjects, the HRs for the first, third, and fourth quartiles were 1.61 (95% CI 0.92–2.81), 1.97 (95% CI 1.17–3.31), and 2.19 (95% CI 1.33–3.59), respectively. In conclusion, we demonstrated that low serum levels of 25OHD are associated with an increased risk of mortality. Serum levels of intact PTH are nonlinearly associated with mortality only in subjects with CKD, with the lowest risk for mortality being evident in the second quartile.
Literature
13.
go back to reference Domiciano DS, Machado LG, Lopes JB et al (2016) bone mineral density and parathyroid hormone as independent risk factors for mortality in community-dwelling older adults: a population-based prospective cohort study in brazil. the sao paulo ageing & health (SPAH) study. J Bone Miner Res 31:1146–1157. https://doi.org/10.1002/jbmr.2795 CrossRefPubMed Domiciano DS, Machado LG, Lopes JB et al (2016) bone mineral density and parathyroid hormone as independent risk factors for mortality in community-dwelling older adults: a population-based prospective cohort study in brazil. the sao paulo ageing & health (SPAH) study. J Bone Miner Res 31:1146–1157. https://​doi.​org/​10.​1002/​jbmr.​2795 CrossRefPubMed
25.
go back to reference Pilz S, Grübler M, Gaksch M et al (2016) Vitamin D and mortality. Anticancer Res 36:1379–1387PubMed Pilz S, Grübler M, Gaksch M et al (2016) Vitamin D and mortality. Anticancer Res 36:1379–1387PubMed
32.
go back to reference Kurz P, Monier-Faugere MC, Bognar B et al (1994) Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855–861CrossRefPubMed Kurz P, Monier-Faugere MC, Bognar B et al (1994) Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855–861CrossRefPubMed
Metadata
Title
Serum level vitamin D and parathyroid hormone, and mortality, with or without chronic kidney disease
Authors
Chang Kyun Choi
Sun-Seog Kweon
Young-Hoon Lee
Hae-Sung Nam
Kyeong-Soo Park
So-Yeon Ryu
Seong-Woo Choi
Sun A. Kim
Min-Ho Shin
Publication date
01-09-2019
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 5/2019
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-018-0979-z

Other articles of this Issue 5/2019

Journal of Bone and Mineral Metabolism 5/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.